Prostatic Hyperplasia
Conditions
Keywords
dutasteride, cross over study, bioavailability
Brief summary
The purpose of this study is to determine the bioavailability of 0.5mg dutasteride novel formulation compared to the currently marketed 0.5mg dutasteride soft gel capsule in fasted healthy male subjects.
Detailed description
The purpose of this study is to determine the bioavailability of 0.5mg dutasteride in a novel formulation compared to the currently marketed 0.5mg dutasteride soft gel capsule in fasted healthy male subjects. This will be an open-label, single dose, randomized, two-period crossover study in healthy male subjects. Subjects will receive a single oral dose 0.5mg novel dutasteride formulation and a single oral dose 0.5mg dutasteride soft gel capsule in a fasted state. Each dose of the study medication will be separated by a 28-day washout period. Blood samples for pharmacokinetic analysis will be taken at regular intervals after dosing. Safety will be assessed by measurement of blood pressure, heart rate, laboratory data, and review of adverse events. The study will enrol approximately 35 healthy male subjects to ensure that 30 subjects complete the study. The study will be conducted in the USA.
Interventions
DRUGdutasteride
novel dutasteride
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
20 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy as determined by a responsible and experienced physician. * Males between 20 and 45 years of age inclusive, at the time of signing the informed consent form. * Male subjects with female partners of child-bearing potential must agree to use one of the contraception. * Body mass index within the range 18-30 kg/m2 (inclusive); weight range 55-95 kg (inclusive). * Capable of giving written informed consent. * Single QTcB \< 450 msec. * Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, and bilirubin less than or equal to 1.5xULN (isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
Exclusion criteria
* History of postural hypotension, dizziness, poor hydration, vertigo, vaso-vagal reactions or any other signs and symptoms of orthostasis. * Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones). * A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening * A positive test for human immunodeficiency virus (HIV) antibody. * Subject is mentally or legally incapacitated. * Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements. * History of sensitivity to dutasteride, components thereof or drugs of this class or a history of drug or other allergy. * History of sensitivity to heparin or heparin-induced thrombocytopenia * The subject has participated in a clinical trial for 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer). * Exposure to more than four new chemical entities within 12 months prior to the first dosing day. * A positive pre-study drug/alcohol screen. * History of regular alcohol consumption. * Consumption of red wine, grapefruit juice, grapefruit and related hybrids, and jufen grapes. * The subject has donated blood or blood products in excess of 500 mL within a 56 day period. * Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months. * Unwillingness or inability to follow the procedures outlined in the protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Bioavailability | Change from Day 1 (session 1) compared to Day 29 (session 2), predose, .25, .5, .75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72 | To assess the dutasteride relative bioavailability of the of 0.5 mg novel formulation compared with the currently marketed 0.5 mg soft gelatin capsule. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety | Changes from screening to 3 months | Changes in blood pressure and pulse rates, review of number of subjects with adverse events, and changes in clinical laboratory data. |
Countries
United States
Outcome results
None listed